First doses of mpox vaccine from the United States arrive in Congo
Authorities in Congo say 50,000 doses of the mpox vaccine from the United States have arrived in the country
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Authorities in Congo said that 50,000 doses of mpox vaccine from the United States arrived in the country on Tuesday, a week after the first batch arrived from the European Union.
Adults in Equateur, South Kivu and Sankuru, the three most affected provinces, will be vaccinated first, starting on Oct. 2, Cris Kacita Osako, coordinator of Congo’s Monkeypox Response Committee, told The Associated Press.
Last week, the first batch of mpox vaccines arrived in the capital of Congo, the center of the outbreak. The 100,000 doses of the JYNNEOS vaccine, manufactured by the Danish company Bavarian Nordic, were donated by the EU through HERA, the bloc’s agency for health emergencies. Another 100,000 were delivered over the weekend.
The 50,000 doses from the U.S. will be of the same JYNNEOS vaccine.
The 250,000 doses are just a fraction of the 3 million doses authorities have said are needed to end the mpox outbreaks in Congo, the epicenter of the global health emergency. EU countries pledged to donate more than 500,000 others, but the timeline for their delivery remained unclear.
Since the start of 2024, there have been 5,549 confirmed mpox cases across the continent, with 643 associated deaths, representing a sharp escalation in both infections and fatalities compared to previous years. The cases in Congo constituted 91% of the total number. Most mpox infections in Congo and Burundi, the second most affected country, are in children under age 15.
Last week, the Africa Center for Disease Control and Prevention and the World Health Organization launched a continent-wide response plan to the outbreak of mpox, three weeks after WHO declared outbreaks in 12 African countries a global emergency.
Congo issued an emergency approval of the vaccine, which has already been used in Europe and the United States in adults. For the moment, the rollout will be reserved for adults, with priority targeted groups being those who have been in close contact with infected people and sex workers, the Africa CDC Director-General Dr. Jean Kaseya told reporters last week.
The European Medicines Agency is examining additional data to be able to administer it to children ranging in age from 12 to 17, which could happen at the end of the month, HERA Director-General Laurent Muschel said.
The next batch of mpox vaccines will come from Japan and could arrive as early as this weekend, Kacita Osako told the AP, without specifying how many doses.